Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction (FHID)

Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated Heart Failure With Ischemic Systolic Dysfunction

The purpose of the study is to investigate the clinical and morphological characteristics of chronic subclinical inflammation in the myocardium in patients with decompensated heart failure with ischemic systolic dysfunction.

Study Overview

• Status: Unknown
• Conditions: Ischemic Heart Disease; Decompensated Heart Failure
• Intervention / Treatment: Procedure: Endomyocardial biopsy

Detailed Description

Important reason for the development of chronic heart failure is a viral disease of the heart, the three phenotypes associated with: the presence of inflammation without viral agent, implying an autoimmune disease; presence of inflammation and persistent viruses; and the presence of persistent virus without signs of inflammation.

There is a group of patients with coronary heart disease, which on the background of optimal treatment is observed progression of clinical symptoms of coronary heart disease with the subsequent development of heart failure, leading to ischemic cardiomyopathy. Perhaps the reason for this is the combination of inflammatory and ischemic cardiomyopathies.

Inflammatory cardiomyopathy, involved in the pathogenesis of DCM, includes idiopathic, autoimmune and infectious subtypes. Inflammatory disease of the myocardium diagnosed by established histological, immunological and immunohistochemical criteria.

This study will include 60 patients with decompensated heart failure with ischemic left ventricular systolic dysfunction (LVEF <40%) were hospitalized not earlier than 6 months after myocardial revascularization. This group of patients will receive standard treatment, according to national guidelines RSC and ESC, to stabilize heart failure. All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy as a result of immunohistochemical studies will be made on the separation of the virus and the virus-negative-positive group. After that, the group will be divided into subgroups: virus - and inflammation in the myocardium inflammation without viral antigen, viral inflammation of the presence of antigen and the group with the presence of viral antigen without any signs of inflammation in the myocardium.

The study is nonrandomized.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Vyacheslav Ryabov, MD, Phd; Phone Number: +73822553689; Email: rvvt@cardio-tomsk.ru
• Study Contact Backup: Name: Ekaterina Krychinkina, MD; Phone Number: +73822558360; Email: katy990@mail.ru

Study Locations

• Russian Federation
  • Tomsk, Russian Federation, 634012
    • Recruiting
    • Scientific and Research Institution of Cardiology of Siberian Department of RAMS
    • Principal Investigator: Vyacheslav Ryabov, MD, PhD
    • Contact: Vyacheslav Ryabov, MD, Phd; Phone Number: +73822553689; Email: rvvt@cardio.tsu.ru
  • Tomskii region
    • Tomsk, Tomskii region, Russian Federation, 634012
      • Recruiting
      • Research Institutite for Cardiology
      • Contact: Vyacheslav Ryabov, MD, Phd; Phone Number: +73822553689; Email: rvvt@cardio-tomsk.ru
      • Principal Investigator: Vyacheslav Ryabov, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men and women over the age of 18 years old and weighing up to 130 kg
• Clinical symptoms of decompensated heart failure in history
• Heart failure decompensation requiring hospitalization for at least 3 of the following symptoms: shortness of breath, or position orthopnea, rales, peripheral edema, jugular venous pulsations, signs of stagnation in the pulmonary circulation according to the X-ray of the chest
• Confirmed coronary heart disease with diastolic dysfunction (LVEF <40%) in history and at the time of admission
• The term of the inclusion of patients in the study did not earlier than six months after revascularization (PCI or CABG)
• Patients receiving medical treatment according to national guidelines RSC and ESC with individually tailored doses of drugs

Exclusion Criteria:

• The refusal of a patient to conduct the necessary studies
• Poor visualization of the heart when ultrasound
• Hemodynamically significant valvular heart disease
• Acute coronary syndrome
• Тhrombosis of the right atrium and right ventricle
• Condition after the operation, impeding access to the right ventricle (cava filters plication vena cava, Mustard or Senning operation on the d-transposition of the great arteries, a mechanical prosthetic tricuspid valve)
• Severe comorbidities

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: chronic inflammation; All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.	Procedure: Endomyocardial biopsy; Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.; Other Names: EMB

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of inflammatory infiltrate in the myocardial tissue	6 month after PCI or CABG

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of the virus - positive inflammatory infiltrate in the myocardial tissue	6 month after PCI or CABG
The most frequent viral agents in myocardial tissue in this region	6 month after PCI or CABG
Incidence of the acute myocardial infarction	6 and 12 month after PCI or CABG
Incidence of disturbance rhythm and conduction of the heart	6 and 12 month after PCI or CABG
Left ventricular ejection fraction (Echo)	6 and 12 month after PCI or CABG
Еnd-diastolic volume of the left ventricle (Echo)	6 and 12 month after PCI or CABG
Еnd-systolic volume of the left ventricle (Echo)	6 and 12 month after PCI or CABG
Incidence of the mortality	6 and 12 month after PCI or CABG
Incidence of the stroke	6 and 12 month after PCI or CABG
Incidence of hospitalizations for decompensation heart failure	6 and 12 month after PCI or CABG

Collaborators and Investigators

• Sponsor: Russian Academy of Medical Sciences
• Investigators: Principal Investigator: Vyacheslav Ryabov, MD, PhD, Research Institute for Cardiology

Study record dates

Study Major Dates

• Study Start: January 1, 2016
• Primary Completion (Anticipated): February 1, 2018
• Study Completion (Anticipated): October 1, 2018

Study Registration Dates

• First Submitted: January 4, 2016
• First Submitted That Met QC Criteria: January 5, 2016
• First Posted (Estimate): January 7, 2016

Study Record Updates

• Last Update Posted (Estimate): January 7, 2016
• Last Update Submitted That Met QC Criteria: January 5, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: ischemic heart disease; inflammatory cardiomyopathy; decompensated heart failure
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Heart Failure; Heart Diseases; Coronary Artery Disease; Myocardial Ischemia; Ischemia; Inflammation
• Other Study ID Numbers: 1801